Sudden Cardiac Death in Patients With Silent Myocardial Ischemia After Myocardial Infarction (from the Swiss Interventional Study on Silent Ischemia Type II [SWISSI II])

American Journal of Cardiology

Volumn 104, Issue 2, 2009, Pages 158-163

  Schoenenberger, Andreas Wolfgang ^a,b   Kobza, Richard ^c   Jamshidi, Peiman ^c   Zuber, Michel ^c   Abbate, Antonio ^d   Stuck, Andreas Ernst ^a,b   Pfisterer, Matthias ^e   Erne, Paul ^c  

^a UNIVERSITY OF BERN   (Switzerland)

^b UNIVERSITY OF BERN   (Switzerland)

^c Luzerner Kantonsspital ^*  (Switzerland)

^d VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

^e UNIVERSITY HOSPITAL BASEL   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; AMLODIPINE; BISOPROLOL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; MOLSIDOMINE;

ADULT; AGE DISTRIBUTION; AGED; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; FOLLOW UP; HEART DEATH; HEART INFARCTION; HEART LEFT VENTRICLE EJECTION FRACTION; HUMAN; HYPERTENSION; INCIDENCE; INTERVENTION STUDY; MAJOR CLINICAL STUDY; MALE; MEDICAL CARE; MINIMAL RESIDUAL DISEASE; PERCUTANEOUS CORONARY INTERVENTION; PREDICTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RECURRENT DISEASE; SILENT MYOCARDIAL ISCHEMIA; SUDDEN DEATH; SWITZERLAND;

ADRENERGIC BETA-ANTAGONISTS; ADULT; AGED; AMLODIPINE; ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; ANTIHYPERTENSIVE AGENTS; BISOPROLOL; DEATH, SUDDEN, CARDIAC; FEMALE; HUMANS; MALE; MIDDLE AGED; MOLSIDOMINE; MULTIVARIATE ANALYSIS; MYOCARDIAL INFARCTION; MYOCARDIAL ISCHEMIA; REGRESSION ANALYSIS; RISK FACTORS; SWITZERLAND; VASODILATOR AGENTS;

EID: 67649407589     PISSN: 00029149     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.amjcard.2009.03.019     Document Type: Article

References (25)

1. Conti C.R. Silent cardiac ischemia. Curr Opin Cardiol 17 (2002) 537-542
2. Cohn P.F. Silent myocardial ischemia: recent developments. Curr Atheroscler Rep 7 (2005) 155-163
3. Cohn P.F., Fox K.M., and Daly C. Silent myocardial ischemia. Circulation 108 (2003) 1263-1277
4. Thaulow E., Erikssen J., Sandvik L., Erikssen G., Jorgensen L., and Cohn P.F. Initial clinical presentation of cardiac disease in asymptomatic men with silent myocardial ischemia and angiographically documented coronary artery disease (the Oslo Ischemia Study). Am J Cardiol 72 (1993) 629-633
5. Erne P., Schoenenberger A.W., Zuber M., Burckhardt D., Kiowski W., Dubach P., Resink T., and Pfisterer M. Effects of anti-ischemic drug therapy in silent myocardial ischemia type I-the Swiss Interventional Study on Silent Ischemia Type I (SWISSI I): a randomized, controlled pilot study. Eur Heart J 28 (2007) 2110-2117
6. Erne P., Schoenenberger A.W., Burckhardt D., Zuber M., Kiowski W., Buser P.T., Dubach P., Resink T.J., and Pfisterer M. Effects of percutaneous coronary interventions in silent ischemia after myocardial infarction: the SWISSI II randomized controlled trial. JAMA 297 (2007) 1985-1991
7. Sheps D.S., and Heiss G. Sudden death and silent myocardial ischemia. Am Heart J 117 (1989) 177-184
8. Pedone C., Elhendy A., Biagini E., van Domburg R.T., Schinkel A.F., Di P.G., Bax J.J., and Poldermans D. Prognostic significance of myocardial ischemia by dobutamine stress echocardiography in patients without angina pectoris after coronary revascularization. Am J Cardiol 102 (2008) 1156-1158
9. Aronow W.S., Ahn C., Mercando A.D., Epstein S., and Kronzon I. Prevalence of and association between silent myocardial ischemia and new coronary events in older men and women with and without cardiovascular disease. J Am Geriatr Soc 50 (2002) 1075-1078
10. Lotze U., Ozbek C., Gerk U., Kaufmann H., Sen S., and Figulla H.R. Three-year follow-up of patients with silent ischemia in the subacute phase of myocardial infarction after thrombolysis and early coronary intervention. Int J Cardiol 71 (1999) 167-178
11. Myerburg R.J., Kessler K.M., Mallon S.M., Cox M.M., de Marchena E., Interian Jr. A., and Castellanos A. Life-threatening ventricular arrhythmias in patients with silent myocardial ischemia due to coronary-artery spasm. N Engl J Med 326 (1992) 1451-1455
12. Hinkle Jr. L.E., and Thaler H.T. Clinical classification of cardiac deaths. Circulation 65 (1982) 457-464
13. Myerburg R.J., Kessler K.M., and Castellanos A. Sudden cardiac death: epidemiology, transient risk, and intervention assessment. Ann Intern Med 119 (1993) 1187-1197
14. Goldberger J.J., Cain M.E., Hohnloser S.H., Kadish A.H., Knight B.P., Lauer M.S., Maron B.J., Page R.L., Passman R.S., Siscovick D., Stevenson W.G., Zipes D.P., and American Heart Association Council on Clinical Cardiology; American Heart Association Council on Epidemiology and Prevention; American College of Cardiology Foundation; Heart Rhythm Society. American Heart Association/American College of Cardiology Foundation/Heart Rhythm Society scientific statement on noninvasive risk stratification techniques for identifying patients at risk for sudden cardiac death: a scientific statement from the American Heart Association Council on Clinical Cardiology Committee on Electrocardiography and Arrhythmias and Council on Epidemiology and Prevention. Heart Rhythm 5 (2008) e1-e21
15. Priori S.G., Aliot E., Blomstrom-Lundqvist C., Bossaert L., Breithardt G., Brugada P., Camm A.J., Cappato R., Cobbe S.M., Di Mario C., Maron B.J., McKenna W.J., Pedersen A.K., Ravens U., Schwartz P.J., Trusz-Gluza M., Vardas P., Wellens H.J., and Zipes D.P. Task Force on Sudden Cardiac Death of the European Society of Cardiology. Eur Heart J 22 (2001) 1374-1450
16. Moss A.J., Hall W.J., Cannom D.S., Daubert J.P., Higgins S.L., Klein H., Levine J.H., Saksena S., Waldo A.L., Wilber D., Brown M.W., and Heo M. Improved survival with an implantable defibrillator in patients with coronary artery disease at high risk for ventricular arrhythmia. N Engl J Med 335 (1996) 1933-1940
17. Moss A.J., Zareba W., Hall W.J., Klein H., Wilber D.J., Cannom D.S., Daubert J.P., Higgins S.L., Brown M.W., Andrews M.L., and Multicenter Automatic Defibrillator Implantation Trial II Investigators. Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction. N Engl J Med 346 (2002) 877-883
18. Bigger Jr. J.T., Fleiss J.L., Kleiger R., Miller J.P., and Rolnitzky L.M. The relationships among ventricular arrhythmias, left ventricular dysfunction, and mortality in the 2 years after myocardial infarction. Circulation 69 (1984) 250-258
19. Mäkikallio T.H., Barthel P., Schneider R., Bauer A., Tapanainen J.M., Tulppo M.P., Perkiömäki J.S., Schmidt G., and Huikuri H.V. Frequency of sudden cardiac death among acute myocardial infarction survivors with optimized medical and revascularization therapy. Am J Cardiol 97 (2006) 480-484
20. Ruta J., Bolińska H., Ptaszyński P., Rosiak M., Wranicz K.J., Kośmider M., Jaszewski R., and Zasłonka J. The impact of very late revascularization of occluded infarct-related artery on cardiac mortality and the incidence of sudden death in survivors of acute myocardial infarction-long-term observation. Med Sci Monit 8 (2002) 364-370
21. Schoenenberger A.W., Erne P., Ammann S., Gillmann G., Kobza R., and Stuck A.E. Prediction of arrhythmic events after myocardial infarction based on signal-averaged electrocardiogram and ejection fraction. Pacing Clin Electrophysiol 31 (2008) 221-228
22. Abbate A., Biondi-Zoccai G.G., Appleton D.L., Erne P., Schoenenberger A.W., Lipinski M.J., Agostoni P., Sheiban I., and Vetrovec G.W. Survival and cardiac remodeling benefits in patients undergoing late percutaneous coronary intervention of the infarct-related artery: evidence from a meta-analysis of randomized controlled trials. J Am Coll Cardiol 51 (2008) 956-964
23. Abbate A., Bussani R., Biondi-Zoccai G.G., Santini D., Petrolini A., De Giorgio F., Vasaturo F., Scarpa S., Severino A., Liuzzo G., Leone A.M., Baldi F., Sinagra G., Silvestri F., Vetrovec G.W., Crea F., Biasucci L.M., and Baldi A. Infarct-related artery occlusion, tissue markers of ischaemia, and increased apoptosis in the peri-infarct viable myocardium. Eur Heart J 26 (2005) 2039-2045
24. Buxton A.E., Lee K.L., Hafley G.E., Pires L.A., Fisher J.D., Gold M.R., Josephson M.E., Lehmann M.H., Prystowsky E.N., and MUSTT Investigators. Limitations of ejection fraction for prediction of sudden death risk in patients with coronary artery disease: lessons from the MUSTT study. J Am Coll Cardiol 50 (2007) 1150-1157
25. Hochman J.S., Lamas G.A., Buller C.E., Dzavik V., Reynolds H.R., Abramsky S.J., Forman S., Ruzyllo W., Maggioni A.P., White H., Sadowski Z., Carvalho A.C., Rankin J.M., Renkin J.P., Steg P.G., Mascette A.M., Sopko G., Pfisterer M.E., Leor J., Fridrich V., Mark D.B., Knatterud G.L., and Occluded Artery Trial Investigators. Coronary intervention for persistent occlusion after myocardial infarction. N Engl J Med 355 (2006) 2395-2407